Merck Serono Announces CHMP Positive Opinion to Extend Kuvan Use to Children with PKU Below 4 Years of Age
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK based media CHMP recommendation based on results from the Phase IIIb SPARK study Merck Serono, the biopharmaceutical business of Merck, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued ...